Tags: Intellectual Property

March 31, 2023

WEBINAR VIDEO | IP license agreements: common pitfalls and key issues

In this webinar, Bart Bollen and Bregt Raus share with you the traps and mistakes that companies make when licensing their intellectual property.

Read on

March 20, 2023

IP license agreements: common pitfalls and key issues

Learn how to identify and address key issues in licensing agreements to avoid legal headaches!

Read on

March 14, 2023

Trademark protection in Web 3.0: Lessons from the Hermès vs. MetaBirkins case

On 8 February 2023, a New York jury delivered its long-awaited verdict in a case brought by the French luxury brand Hermès, against the artist Mason Rothschild.

Read on

January 16, 2023

When are IP holders liable for enforcing a later invalidated IP right?

At this IP Update, our IP specialists, Christophe Ronse and Kirian Claeyé, will discuss under what circumstances IP holders may be held liable for enforcing a later invalidated IP right.

Read on

December 21, 2022

WEBINAR VIDEO | What do the CJEU’s decisions on parallel trade of medicines mean for your company?

At this additional Christmas edition, the IP specialists in our Life Sciences team discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.

Read on

December 6, 2022

What do the CJEU’s decisions on parallel trade of medicines mean for your company?

At this additional Christmas edition, the IP specialists in our Life Sciences team will discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.

Read on

December 2, 2022

Are parallel importers necessarily allowed to rebox medicines in case of visible traces from ATDs? The CJEU says NO

Pharmaceutical companies are obliged to affix an anti-tampering device (‘ATD’) on prescription-only medicines to enable verification of whether a medicine’s packaging has been tampered with. Parallel importers argue that this results in an overarching objective necessity to ‘rebox’ such medicines.

Read on

November 24, 2022

Can parallel importers (re)brand generic medicines? The CJEU limits the ‘room for manoeuvre’

If a branded medicine and its generic version are put on the EEA market by economically-linked undertakings, is a parallel importer then allowed to rebrand and repackage the imported generic version as the branded reference medicine? After the Brussels Court of Appeal had referred questions on this issue for a preliminary ruling two years ago, the CJEU has now clarified the limits.

Read on

August 5, 2022

Copyright fit for the internet age? Belgium implements the DSM directive (Part 3: New rules governing copyright contracts)

On 1 August 2022, the Belgian law transposing the Directive on Copyright in the Digital Single Market (“DSM directive”) (EU Directive 2019/790) was published in the Belgian State Gazette (NL / FR). The new law enters into effect immediately (with the exception of a few provisions).

Read on

August 4, 2022

Copyright fit for the internet age? Belgium implements the DSM directive (Part 2: New neighbouring right for press publishers & four new mandatory exceptions to copyright)

On 1 August 2022, the Belgian law transposing the Directive on Copyright in the Digital Single Market (“DSM directive”) (EU Directive 2019/790) was published in the Belgian State Gazette (NL / FR). The new law enters into effect immediately (with the exception of a few provisions).

Read on

August 3, 2022

Copyright fit for the internet age? Belgium implements the DSM directive (Part 1: Background & article 17 DSM directive)

On 1 August 2022, the Belgian law transposing the Directive on Copyright in the Digital Single Market (“DSM directive”) (EU Directive 2019/790) was published in the Belgian State Gazette. The new law enters into effect immediately (with the exception of a few provisions).

Read on